Orchestra BioMed (NASDAQ:OBIO) Insider Darren Sherman Sells 15,000 Shares

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) insider Darren Sherman sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $4.09, for a total transaction of $61,350.00. Following the transaction, the insider owned 1,154,327 shares of the company’s stock, valued at $4,721,197.43. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Darren Sherman also recently made the following trade(s):

• On Monday, June 1st, Darren Sherman sold 15,000 shares of Orchestra BioMed stock. The shares were sold at an average price of $3.87, for a total value of $58,050.00.

Orchestra BioMed Stock Up 3.6%

OBIO opened at $4.27 on Wednesday. The firm has a market cap of $255.69 million, a P/E ratio of -4.40 and a beta of 0.50. The business’s fifty day simple moving average is $3.96 and its 200 day simple moving average is $4.10. Orchestra BioMed Holdings, Inc. has a 52 week low of $2.20 and a 52 week high of $5.42. The company has a quick ratio of 7.01, a current ratio of 7.03 and a debt-to-equity ratio of 0.35.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.07. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. As a group, equities research analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.47 EPS for the current fiscal year.

Institutional Trading of Orchestra BioMed

A number of institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Orchestra BioMed in the fourth quarter worth $38,000. Creative Planning acquired a new position in shares of Orchestra BioMed during the 2nd quarter valued at $40,000. XTX Topco Ltd purchased a new stake in Orchestra BioMed during the 2nd quarter worth $45,000. Jane Street Group LLC purchased a new stake in Orchestra BioMed during the 2nd quarter worth $50,000. Finally, Virtu Financial LLC acquired a new stake in Orchestra BioMed in the 4th quarter valued at $57,000. Institutional investors and hedge funds own 53.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on OBIO shares. Wall Street Zen lowered Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Orchestra BioMed in a research note on Friday, July 17th. Barclays raised their price target on Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Orchestra BioMed in a report on Thursday, May 14th. Finally, B. Riley Financial dropped their price objective on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.60.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.